Daiichi Sankyo receives Swiss approval for stroke-preventing medicine
Japanese drug major Daiichi Sankyo (TYO: 4568) has received approval in Switzerland for Lixiana (edoxaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
It has also received marketing authorization in Switzerland for the treatment of adult patients with venous thromboembolism, including deep vein thrombosis and pulmonary embolism following previous treatment with fractionated or unfractionated heparin for five days, as well as for the prevention of recurrent venous thromboembolism.
Lixiana is an oral, once-daily selective Xa inhibitor, and the Swiss approvals are based on data from the Phase III ENGAGE AF-TIMI 48 and Hokusai-VTE studies. It was approved and launched in Japan in 2011.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze